Current uric acid detection methodologies lack the requisite sensitivity and selectivity for point-of-care applications. Plasmonic sensors, while promising, demand refinement for improved performance. This work introduces a biofunctionalized sensor predicated on surface plasmon resonance to quantify uric acid within physiologically relevant concentration ranges. The sensor employs the covalent immobilization of uricase enzyme using 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and N-Hydroxysuccinimide (NHS) crosslinking agents, ensuring the durable adherence of the enzyme onto the sensor probe. Characterization through atomic force microscopy and Fourier transform infrared spectroscopy validate surface alterations. The Langmuir adsorption isotherm model elucidates binding kinetics, revealing a sensor binding affinity of 298.83 (mg/dL), and a maximum adsorption capacity of approximately 1.0751°. The biofunctionalized sensor exhibits a sensitivity of 0.0755°/(mg/dL), a linear correlation coefficient of 0.8313, and a limit of detection of 0.095 mg/dL. Selectivity tests against potentially competing interferents like glucose, ascorbic acid, urea, D-cystine, and creatinine showcase a significant resonance angle shift of 1.1135° for uric acid compared to 0.1853° for interferents at the same concentration. Significantly, at a low uric acid concentration of 0.5 mg/dL, a distinct shift of 0.3706° was observed, setting it apart from the lower values noticed at higher concentrations for all typical interferent samples. The uricase enzyme significantly enhances plasmonic sensors for uric acid detection, showcasing a seamless integration of optical principles and biological recognition elements. These sensors hold promise as vital tools in clinical and point-of-care settings, offering transformative potential in biosensing technologies and the potential to revolutionize healthcare outcomes in biomedicine.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.bios.2024.116486 | DOI Listing |
Am J Transl Res
December 2024
Department of Cardiology, Wuhan Asia Heart Hospital Wuhan 430022, Hubei, China.
Objective: To evaluate the impact and prognosis of a multidisciplinary discharge preparation service model for patients with chronic heart failure.
Methods: A total of 100 patients with chronic heart failure who visited the Wuhan Asia Heart Hospital from January 2022 to September 2023 were included. The patients were divided into an experimental group, receiving a multidisciplinary discharge preparation service, and a control group, receiving conventional treatment.
Am J Transl Res
December 2024
Department of Pathology, Cangzhou People's Hospital Cangzhou 061000, Hebei, China.
Objective: To assess the predictive value of peripheral blood inflammatory markers for delayed cerebral ischemia (DCI) in patients with intracerebral hemorrhage (ICH) and explore methods for early intervention.
Methods: This single-center retrospective study reviewed medical records of ICH patients admitted to Cangzhou People's Hospital over a 12-month period from January 2022 to December 2023. Of the 150 identified patients with ICH, including 80 patients without DCI (control group) and 70 with DCI (observation group).
Am J Transl Res
December 2024
Department of Urology, Meizhou People's Hospital (Huangtang Hospital) Meizhou 514031, Guangdong, China.
Objective: To investigate the composition of urinary calculi and its correlation with sex, age, calculi site, urine pH, and underlying diseases.
Methods: The clinical data of 300 patients with urinary calculi admitted to Meizhou People's Hospital from January 2022 to October 2024 were retrospectively analyzed. The composition of urinary calculi and its correlation with sex, age, calculi site, urine pH, and underlying diseases were examined.
Clin Rheumatol
January 2025
Department of Pharmacy Practice and Administrative Sciences, L.S. Skaggs College of Pharmacy, Idaho State University, 1311 E Central Dr, Meridian, ID, 83642, USA.
Scand J Rheumatol
January 2025
Division of Rheumatology, University of Washington, Seattle, WA, USA.
Objective: Although gout is the most common inflammatory arthritis, there are few tools to monitor disease activity and predict complications in gout patients. The neutrophil-to-lymphocyte ratio (NLR) and monocyte-to-lymphocyte ratio (MLR) are associated with disease activity in various diseases and the NLR has been shown to predict coronary artery disease severity, a common comorbid condition with gout. Thus, we evaluated the use of NLR and MLR as novel biomarkers to measure disease activity and predict cardiovascular disease (CVD) risk in gout patients.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!